Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
暂无分享,去创建一个
F. de Braud | G. Bianchi | F. Corti | G. Capri | C. Vernieri | F. Nichetti | F. Ligorio | E. Zattarin | C. Rea | S. Manglaviti